CO2023014316A2 - Anticuerpos anti-clec12a y usos de los mismos - Google Patents
Anticuerpos anti-clec12a y usos de los mismosInfo
- Publication number
- CO2023014316A2 CO2023014316A2 CONC2023/0014316A CO2023014316A CO2023014316A2 CO 2023014316 A2 CO2023014316 A2 CO 2023014316A2 CO 2023014316 A CO2023014316 A CO 2023014316A CO 2023014316 A2 CO2023014316 A2 CO 2023014316A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- fragments
- fusion proteins
- clec12a
- leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179755P | 2021-04-26 | 2021-04-26 | |
| PCT/US2022/026175 WO2022232044A2 (en) | 2021-04-26 | 2022-04-25 | Anti-clec12a antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014316A2 true CO2023014316A2 (es) | 2023-11-20 |
Family
ID=81648460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014316A CO2023014316A2 (es) | 2021-04-26 | 2023-10-25 | Anticuerpos anti-clec12a y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12600784B2 (https=) |
| EP (1) | EP4330284A2 (https=) |
| JP (1) | JP2024516645A (https=) |
| KR (1) | KR20240004286A (https=) |
| CN (1) | CN117545774A (https=) |
| AR (1) | AR125451A1 (https=) |
| AU (1) | AU2022266584A1 (https=) |
| BR (1) | BR112023020365A2 (https=) |
| CA (1) | CA3216770A1 (https=) |
| CL (2) | CL2023003177A1 (https=) |
| CO (1) | CO2023014316A2 (https=) |
| EC (1) | ECSP23088759A (https=) |
| IL (1) | IL307939A (https=) |
| MX (1) | MX2023011710A (https=) |
| PE (1) | PE20241789A1 (https=) |
| PH (1) | PH12023552669A1 (https=) |
| TW (1) | TW202309084A (https=) |
| WO (1) | WO2022232044A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023011712A (es) | 2021-04-26 | 2023-10-12 | Millennium Pharm Inc | Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos. |
| CA3212596A1 (en) | 2021-04-26 | 2022-11-03 | Michel Sadelain | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
| WO2024254778A1 (en) * | 2023-06-14 | 2024-12-19 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against cll1 and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2096750T3 (es) | 1990-10-31 | 1997-03-16 | Somatix Therapy Corp | Vectores retroviricos utiles para la terapia genica. |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| DE60135352D1 (de) | 2000-08-30 | 2008-09-25 | Univ Johns Hopkins | Vorrichtung zur intraokularen wirkstoffverabreichung |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| WO2003022330A2 (en) | 2001-09-12 | 2003-03-20 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
| US20060167435A1 (en) | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| JP2010533181A (ja) | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦα阻害剤の肺投与のための方法及び組成物 |
| JP5932670B2 (ja) | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| EP2622074B1 (en) | 2010-09-30 | 2014-11-12 | Board Of Trustees Of Northern Illinois University | Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| US10501545B2 (en) * | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| EA202090718A1 (ru) | 2017-09-14 | 2020-07-01 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
| WO2019108065A1 (en) * | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| MX2020007338A (es) * | 2018-01-09 | 2020-11-06 | H Lee Moffitt Cancer Ct & Res | Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a. |
| SG11202106765XA (en) * | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-pd-1 binding proteins and methods of use thereof |
| BR112021020999A2 (pt) * | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CA3212596A1 (en) | 2021-04-26 | 2022-11-03 | Michel Sadelain | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
| MX2023011712A (es) | 2021-04-26 | 2023-10-12 | Millennium Pharm Inc | Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos. |
-
2022
- 2022-04-25 CA CA3216770A patent/CA3216770A1/en active Pending
- 2022-04-25 PE PE2023002945A patent/PE20241789A1/es unknown
- 2022-04-25 PH PH1/2023/552669A patent/PH12023552669A1/en unknown
- 2022-04-25 AU AU2022266584A patent/AU2022266584A1/en active Pending
- 2022-04-25 CN CN202280030746.XA patent/CN117545774A/zh active Pending
- 2022-04-25 KR KR1020237034368A patent/KR20240004286A/ko active Pending
- 2022-04-25 MX MX2023011710A patent/MX2023011710A/es unknown
- 2022-04-25 IL IL307939A patent/IL307939A/en unknown
- 2022-04-25 AR ARP220101069A patent/AR125451A1/es unknown
- 2022-04-25 EP EP22723304.6A patent/EP4330284A2/en active Pending
- 2022-04-25 US US17/728,664 patent/US12600784B2/en active Active
- 2022-04-25 WO PCT/US2022/026175 patent/WO2022232044A2/en not_active Ceased
- 2022-04-25 BR BR112023020365A patent/BR112023020365A2/pt unknown
- 2022-04-25 JP JP2023565839A patent/JP2024516645A/ja active Pending
- 2022-04-26 TW TW111115839A patent/TW202309084A/zh unknown
-
2023
- 2023-10-24 CL CL2023003177A patent/CL2023003177A1/es unknown
- 2023-10-25 CO CONC2023/0014316A patent/CO2023014316A2/es unknown
- 2023-11-23 EC ECSENADI202388759A patent/ECSP23088759A/es unknown
-
2025
- 2025-07-24 CL CL2025002212A patent/CL2025002212A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230111279A1 (en) | 2023-04-13 |
| WO2022232044A2 (en) | 2022-11-03 |
| ECSP23088759A (es) | 2024-01-31 |
| US12600784B2 (en) | 2026-04-14 |
| AU2022266584A1 (en) | 2023-10-12 |
| PH12023552669A1 (en) | 2024-02-19 |
| CL2025002212A1 (es) | 2025-10-24 |
| CA3216770A1 (en) | 2022-11-03 |
| IL307939A (en) | 2023-12-01 |
| WO2022232044A3 (en) | 2022-12-08 |
| AR125451A1 (es) | 2023-07-19 |
| TW202309084A (zh) | 2023-03-01 |
| AU2022266584A9 (en) | 2023-10-26 |
| EP4330284A2 (en) | 2024-03-06 |
| BR112023020365A2 (pt) | 2023-11-21 |
| JP2024516645A (ja) | 2024-04-16 |
| KR20240004286A (ko) | 2024-01-11 |
| MX2023011710A (es) | 2023-10-12 |
| CN117545774A (zh) | 2024-02-09 |
| CL2023003177A1 (es) | 2024-05-24 |
| PE20241789A1 (es) | 2024-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23088752A (es) | Anticuerpos anti-adgre2 y usos de los mismos | |
| CO2023014316A2 (es) | Anticuerpos anti-clec12a y usos de los mismos | |
| UY37591A (es) | Conjugados de fármaco anticuerpo | |
| DOP2017000047A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| CL2024003715A1 (es) | Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso. | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20211860A1 (es) | Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso | |
| CL2019003520A1 (es) | Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso. | |
| MX2019014465A (es) | Anticuerpos especificos para flt3 y sus usos. | |
| ECSP20082991A (es) | Agentes aglutinantes del psma y usos de estos | |
| MX2020000342A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos. | |
| UY37698A (es) | Proteínas de unión a antígenos trem2 y usos de estas | |
| AR116718A1 (es) | Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica | |
| MX2021007768A (es) | Anticuerpos anti-ctla4 y metodos de uso de los mismos. | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| MX374810B (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos | |
| PE20190510A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| MX2019011961A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
| UY36539A (es) | Proteínas de unión a icos | |
| AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
| CO2022009737A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| MX2020013122A (es) | Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47). | |
| MX2020013428A (es) | Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana. | |
| BR112022011824A2 (pt) | Anticorpos de cadeia pesada que se ligam a cd38 | |
| EA202092302A1 (ru) | Антитела к trem-1 и их применения |